From Lab to Patient: Optimising Oncology Formulations with Purified Excipients

Join us for an exclusive webinar on Tuesday 25 June 2024 to discover the impact of highly purified, Super Refined™ excipients on the stability and performance of several well-known small molecule chemotherapeutic formulations.

The challenge:
Degradation and instability in chemotherapeutics can lead to extended development timelines, regulatory challenges, and compromised product efficacy. This delays lifesaving treatments for those who need it most—the patients. 

Join to learn:
During this webinar, we will evaluate stability data of several small molecule drugs for cancer belonging to the microtubule inhibitor drug class (docetaxel, paclitaxel), topoisomerase inhibitors (etoposide), as well as hormone-based oncology drugs (fulvestrant). We will show you how we can optimise oncological drug delivery resulting in long-term formulation stability, extended drug shelf life, and ultimately improved drug performance and efficacy. 

Key topics:

• Presentation on our offerings for small molecule API delivery, with a focus on the parenteral administration route and the role of purity.
• Evaluation of the stability of several well-known small molecule APIs for oncology formulated with Super Refined™ versus standard, compendial-grade excipients.
• Preview of our offerings for large molecule therapy development for oncology, such as mAbs and nucleic acid-based cancer therapies, from upstream to downstream biomanufacturing.

Who should attend? 
This webinar will benefit professionals across all stages of oncology drug development: formulation scientists, research scientists, drug product developers and pharmaceutical engineers.

Together, let's unlock new solutions to your most pressing challenges in oncology drug development and redefine the boundaries of what is possible in the fight against cancer.